{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:30:12Z","timestamp":1790857812293,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170223"],"award-info":[{"award-number":["82170223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"crossref","award":["2024AFD421"],"award-info":[{"award-number":["2024AFD421"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00277-025-06344-8","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T03:28:11Z","timestamp":1744342091000},"page":"2593-2603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Alemtuzumab for haematological malignancies"],"prefix":"10.1007","volume":"104","author":[{"given":"Ning","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangqi","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"3","key":"6344_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/cei.13208","volume":"194","author":"Z Li","year":"2018","unstructured":"Li Z, Richards S, Surks HK, Jacobs A, Panzara MA (2018) Clinical Pharmacology of alemtuzumab, an anti-CD52 Immunomodulator, in multiple sclerosis. Clin Exp Immunol 194(3):295\u2013314. https:\/\/doi.org\/10.1111\/cei.13208","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"6344_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00011-017-1032-8","volume":"66","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Su H, Shen X, Du J, Zhang X, Zhao Y (2017) The immunological function of CD52 and its targeting in organ transplantation. Inflamm Res 66(7):571\u2013578. https:\/\/doi.org\/10.1007\/s00011-017-1032-8","journal-title":"Inflamm Res"},{"issue":"2","key":"6344_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","volume":"145","author":"L Jiang","year":"2009","unstructured":"Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC et al (2009) Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 145(2):173\u2013179. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07606.x","journal-title":"Br J Haematol"},{"issue":"2","key":"6344_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","volume":"17","author":"H Lassmann","year":"2007","unstructured":"Lassmann H, Br\u00fcck W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17(2):210\u2013218. https:\/\/doi.org\/10.1111\/j.1750-3639.2007.00064.x","journal-title":"Brain Pathol"},{"issue":"10","key":"6344_CR5","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood.v99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99(10):3554\u20133561. https:\/\/doi.org\/10.1182\/blood.v99.10.3554","journal-title":"Blood"},{"issue":"10","key":"6344_CR6","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","volume":"27","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L et al (2021) CRISPR\/Cas9-Engineered universal CD19\/CD22 Dual-Targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res 27(10):2764\u20132772. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3863","journal-title":"Clin Cancer Res"},{"key":"6344_CR7","doi-asserted-by":"publisher","unstructured":"Boulianne GL, Hozumi N, Shulman MJ Production of functional chimaeric mouse\/human antibody. Nat 1984 Dec 13\u201319;312(5995):643\u20136. https:\/\/doi.org\/10.1038\/312643a0","DOI":"10.1038\/312643a0"},{"issue":"3","key":"6344_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/146532401753174098","volume":"3","author":"G Hale","year":"2001","unstructured":"Hale G (2001) The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 3(3):137\u2013143. https:\/\/doi.org\/10.1080\/146532401753174098","journal-title":"Cytotherapy"},{"issue":"6","key":"6344_CR9","doi-asserted-by":"publisher","first-page":"e39416","DOI":"10.1371\/journal.pone.0039416","volume":"7","author":"SP Rao","year":"2012","unstructured":"Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T et al (2012) Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS ONE 7(6):e39416. https:\/\/doi.org\/10.1371\/journal.pone.0039416","journal-title":"PLoS ONE"},{"issue":"2","key":"6344_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","volume":"128","author":"Y Hu","year":"2009","unstructured":"Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL et al (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 Transgenic mouse model. Immunology 128(2):260\u2013270. https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03115.x","journal-title":"Immunology"},{"issue":"10","key":"6344_CR11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00277-004-0917-0","volume":"83","author":"M Stanglmaier","year":"2004","unstructured":"Stanglmaier M, Reis S, Hallek M (2004) Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 83(10):634\u2013645. https:\/\/doi.org\/10.1007\/s00277-004-0917-0","journal-title":"Ann Hematol"},{"issue":"1","key":"6344_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clim.2011.04.006","volume":"142","author":"L Klotz","year":"2012","unstructured":"Klotz L, Meuth SG, Wiendl H (2012) Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 142(1):25\u201330. https:\/\/doi.org\/10.1016\/j.clim.2011.04.006","journal-title":"Clin Immunol"},{"issue":"12","key":"6344_CR13","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1586\/ern.10.135","volume":"10","author":"EJ Fox","year":"2010","unstructured":"Fox EJ (2010) Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother 10(12):1789\u20131797. https:\/\/doi.org\/10.1586\/ern.10.135","journal-title":"Expert Rev Neurother"},{"issue":"24","key":"6344_CR14","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1212\/WNL.0000000000000520","volume":"82","author":"O Kousin-Ezewu","year":"2014","unstructured":"Kousin-Ezewu O, Azzopardi L, Parker RA, Tuohy O, Compston A, Coles A et al (2014) Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology 82(24):2158\u20132164. https:\/\/doi.org\/10.1212\/WNL.0000000000000520","journal-title":"Neurology"},{"issue":"3","key":"6344_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","volume":"83","author":"GA Hill-Cawthorne","year":"2012","unstructured":"Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J et al (2012) Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 83(3):298\u2013304. https:\/\/doi.org\/10.1136\/jnnp-2011-300826","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"6344_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","volume":"30","author":"SA Thompson","year":"2010","unstructured":"Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ (2010) B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 30(1):99\u2013105. https:\/\/doi.org\/10.1007\/s10875-009-9327-3","journal-title":"J Clin Immunol"},{"issue":"35","key":"6344_CR17","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"25","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al (2007) Alemtuzumab compared with Chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25(35):5616\u20135623. https:\/\/doi.org\/10.1200\/JCO.2007.12.9098","journal-title":"J Clin Oncol"},{"issue":"6","key":"6344_CR18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3760\/cma.j.issn.0253-2727.2015.06.021","volume":"36","author":"M Chen","year":"2015","unstructured":"Chen M, Zhang L, Jia Y, Liu F, Li J, Zhang D et al (2015) T-cell prolymphocytic leukemia treated with alemtuzumab and followed by autologous hematopoietic stem cell transplantation: a case report. Zhonghua Xue Ye Xue Za Zhi 36(6):536. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2015.06.021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"6344_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/jjco\/hyw146","volume":"47","author":"K Ishizawa","year":"2017","unstructured":"Ishizawa K, Fukuhara N, Nakaseko C, Chiba S, Ogura M, Okamoto A et al (2017) Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Jpn J Clin Oncol 47(1):54\u201360. https:\/\/doi.org\/10.1093\/jjco\/hyw146","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"6344_CR20","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ctrv.2012.02.006","volume":"38","author":"MM Cheng","year":"2012","unstructured":"Cheng MM, Goulart B, Veenstra DL, Blough DK, Devine EB (2012) A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia. Cancer Treat Rev 38(8):1004\u20131011. https:\/\/doi.org\/10.1016\/j.ctrv.2012.02.006","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"6344_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ctrv.2014.11.004","volume":"41","author":"P Ladyzynski","year":"2015","unstructured":"Ladyzynski P, Molik M, Foltynski P (2015) A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. Cancer Treat Rev 41(2):77\u201393. https:\/\/doi.org\/10.1016\/j.ctrv.2014.11.004","journal-title":"Cancer Treat Rev"},{"issue":"28","key":"6344_CR22","doi-asserted-by":"publisher","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","volume":"23","author":"T Elter","year":"2005","unstructured":"Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R et al (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23(28):7024\u20137031. https:\/\/doi.org\/10.1200\/JCO.2005.01.9950","journal-title":"J Clin Oncol"},{"issue":"15","key":"6344_CR23","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1182\/blood-2011-05-351833","volume":"118","author":"M Montillo","year":"2011","unstructured":"Montillo M, Tedeschi A, Petrizzi VB, Ricci F, Crugnola M, Spriano M et al (2011) An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed\/refractory patients with B-cell chronic lymphocytic leukemia. Blood 118(15):4079\u20134085. https:\/\/doi.org\/10.1182\/blood-2011-05-351833","journal-title":"Blood"},{"issue":"21","key":"6344_CR24","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1182\/blood-2014-01-547737","volume":"123","author":"CH Geisler","year":"2014","unstructured":"Geisler CH, van T\u2019 Veer MB, Jurlander J, Walewski J, Tj\u00f8nnfjord G, It\u00e4l\u00e4 Remes M et al (2014) Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood 123(21):3255\u20133262. https:\/\/doi.org\/10.1182\/blood-2014-01-547737","journal-title":"Blood"},{"key":"6344_CR25","doi-asserted-by":"publisher","first-page":"547582","DOI":"10.1155\/2009\/547582","volume":"2009","author":"WY Hwang","year":"2009","unstructured":"Hwang WY, Dearden C, Loh YS, Linn YC, Tien SL, Teoh GK et al (2009) Outpatient-based therapy of oral fludarabine and subcutaneous alemtuzumab for Asian patients with relapsed\/refractory chronic lymphocytic leukemia. Adv Hematol 2009:547582. https:\/\/doi.org\/10.1155\/2009\/547582","journal-title":"Adv Hematol"},{"issue":"8","key":"6344_CR26","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/cncr.23824","volume":"113","author":"CS Zent","year":"2008","unstructured":"Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA et al (2008) Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 113(8):2110\u20132118. https:\/\/doi.org\/10.1002\/cncr.23824","journal-title":"Cancer"},{"issue":"12","key":"6344_CR27","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.3324\/haematol.2019.230805","volume":"105","author":"AR Pettitt","year":"2020","unstructured":"Pettitt AR, Jackson R, Cicconi S, Polydoros F, Yap C, Dodd J et al (2020) Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. Haematologica 105(12):2868\u20132871. https:\/\/doi.org\/10.3324\/haematol.2019.230805","journal-title":"Haematologica"},{"issue":"29","key":"6344_CR28","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1200\/JCO.2010.29.7978","volume":"28","author":"TS Lin","year":"2010","unstructured":"Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM et al (2010) Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 28(29):4500\u20134506. https:\/\/doi.org\/10.1200\/JCO.2010.29.7978","journal-title":"J Clin Oncol"},{"issue":"3","key":"6344_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/ejh.12825","volume":"98","author":"O Al-Sawaf","year":"2017","unstructured":"Al-Sawaf O, Fischer K, Herling CD, Ritgen M, B\u00f6ttcher S, Bahlo J et al (2017) Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I\/II multicentre trial. Eur J Haematol 98(3):254\u2013262. https:\/\/doi.org\/10.1111\/ejh.12825","journal-title":"Eur J Haematol"},{"issue":"3","key":"6344_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.blre.2014.02.001","volume":"28","author":"SN Steinway","year":"2014","unstructured":"Steinway SN, LeBlanc F, Loughran TP Jr (2014) The pathogenesis and treatment of large granular lymphocyte leukemia. Blood Rev 28(3):87\u201394. https:\/\/doi.org\/10.1016\/j.blre.2014.02.001","journal-title":"Blood Rev"},{"issue":"4","key":"6344_CR31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1365-2141.2010.08218.x","volume":"150","author":"H Olteanu","year":"2010","unstructured":"Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P (2010) Efficacy and safety of long-term (>\u20097 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. Br J Haematol 150(4):480\u2013481. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08218.x","journal-title":"Br J Haematol"},{"issue":"8","key":"6344_CR32","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/j.leukres.2010.01.019","volume":"34","author":"H Monjanel","year":"2010","unstructured":"Monjanel H, Hourioux C, Arbion F, Colombat P, Lissandre S, Regner MP et al (2010) Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment. Leuk Res 34(8):e197\u2013e199. https:\/\/doi.org\/10.1016\/j.leukres.2010.01.019","journal-title":"Leuk Res"},{"issue":"1","key":"6344_CR33","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/S2352-3026(15)00227-6","volume":"3","author":"B Dumitriu","year":"2016","unstructured":"Dumitriu B, Ito S, Feng X, Stephens N, Yunce M, Kajigaya S et al (2016) Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. Lancet Haematol 3(1):e22\u2013e29. https:\/\/doi.org\/10.1016\/S2352-3026(15)00227-6","journal-title":"Lancet Haematol"},{"issue":"1","key":"6344_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/1078-0432.CCR-16-1022","volume":"23","author":"K Sharma","year":"2017","unstructured":"Sharma K, Janik JE, O\u2019Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M et al (2017) Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-Associated adult T-cell leukemia\/lymphoma. Clin Cancer Res 23(1):35\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6344_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","volume":"35","author":"GG Wulf","year":"2021","unstructured":"Wulf GG, Altmann B, Ziepert M, D\u2019Amore F, Held G, Greil R et al (2021) Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial. Leukemia 35(1):143\u2013155. https:\/\/doi.org\/10.1038\/s41375-020-0838-5","journal-title":"Leukemia"},{"issue":"1","key":"6344_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","volume":"60","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ et al (2007) Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 60(1):129\u2013134. https:\/\/doi.org\/10.1007\/s00280-007-0469-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"6344_CR37","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s10637-010-9523-2","volume":"30","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Kim K, Park Y, Kim BS, Huh J, Ko YH et al (2012) Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Invest New Drugs 30(1):368\u2013375. https:\/\/doi.org\/10.1007\/s10637-010-9523-2","journal-title":"Invest New Drugs"},{"key":"6344_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3760\/cma.j.issn.1009-9921.2010.05.022","volume":"5","author":"N Liu","year":"2010","unstructured":"Liu N, Zou W, Sun Q, Song X, Li G (2010) Topical nitrogen mustard combined with intravenous infusion of alemtuzumab in the treatment of a case of cutaneous T-cell lymphoma. Leuk Lymphoma 5:320\u2013320. https:\/\/doi.org\/10.3760\/cma.j.issn.1009-9921.2010.05.022","journal-title":"Leuk Lymphoma"},{"key":"6344_CR39","doi-asserted-by":"publisher","first-page":"706278","DOI":"10.3389\/fimmu.2021.706278","volume":"12","author":"N Kashani","year":"2021","unstructured":"Kashani N, Kelland EE, Vajdi B, Anderson LM, Gilmore W, Lund BT (2021) Immune regulatory cell bias following alemtuzumab treatment in Relapsing-Remitting multiple sclerosis. Front Immunol 12:706278. https:\/\/doi.org\/10.3389\/fimmu.2021.706278","journal-title":"Front Immunol"},{"issue":"3","key":"6344_CR40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00277-009-0816-5","volume":"89","author":"D G\u00f3mez-Almaguer","year":"2010","unstructured":"G\u00f3mez-Almaguer D, Jaime-P\u00e9rez JC, Garza-Rodr\u00edguez V, Chapa-Rodr\u00edguez A, Tar\u00edn-Arzaga L, Herrera-Garza JL et al (2010) Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Ann Hematol 89(3):299\u2013303. https:\/\/doi.org\/10.1007\/s00277-009-0816-5","journal-title":"Ann Hematol"},{"issue":"2","key":"6344_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.leukres.2008.08.004","volume":"33","author":"H Kim","year":"2009","unstructured":"Kim H, Min YJ, Baek JH, Shin SJ, Lee EH, Noh EK et al (2009) A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 33(2):222\u2013231. https:\/\/doi.org\/10.1016\/j.leukres.2008.08.004","journal-title":"Leuk Res"},{"issue":"6","key":"6344_CR42","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/ajh.26924","volume":"98","author":"N Aggarwal","year":"2023","unstructured":"Aggarwal N, Manley AL, Shalhoub R, Durrani J, Rios O, Lotter J et al (2023) Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study. Am J Hematol 98(6):932\u2013939. https:\/\/doi.org\/10.1002\/ajh.26924","journal-title":"Am J Hematol"},{"issue":"6","key":"6344_CR43","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1182\/blood-2003-12-4207","volume":"104","author":"AY Ho","year":"2004","unstructured":"Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al (2004) Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, Busulphan, and alemtuzumab (FBC) conditioning. Blood 104(6):1616\u20131623. https:\/\/doi.org\/10.1182\/blood-2003-12-4207","journal-title":"Blood"},{"issue":"5","key":"6344_CR44","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.bbmt.2009.01.021","volume":"15","author":"K Van Besien","year":"2009","unstructured":"Van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B et al (2009) Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transpl 15(5):610\u2013617. https:\/\/doi.org\/10.1016\/j.bbmt.2009.01.021","journal-title":"Biol Blood Marrow Transpl"},{"issue":"24","key":"6344_CR45","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1200\/JCO.2005.15.602","volume":"23","author":"K Van Besien","year":"2005","unstructured":"Van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L et al (2005) Fludarabine, Melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5728\u20135738. https:\/\/doi.org\/10.1200\/JCO.2005.15.602","journal-title":"J Clin Oncol"},{"issue":"20","key":"6344_CR46","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1182\/bloodadvances","volume":"3","author":"VS Sheth","year":"2019","unstructured":"Sheth VS, Potter V, Gandhi SA, Kulasekararaj AG, de Lavallade H, Muus P et al (2019) Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years. Blood Adv 3(20):3070\u20133079. https:\/\/doi.org\/10.1182\/bloodadvances","journal-title":"Blood Adv"},{"issue":"3","key":"6344_CR47","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/bmt.2016.272","volume":"52","author":"P Tsirigotis","year":"2017","unstructured":"Tsirigotis P, Liga M, Gkirkas K, Stamouli M, Triantafyllou E, Marangos M et al (2017) Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia. Bone Marrow Transpl 52(3):445\u2013451. https:\/\/doi.org\/10.1038\/bmt.2016.272","journal-title":"Bone Marrow Transpl"},{"issue":"16","key":"6344_CR48","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1182\/bloodadvances.2023010973","volume":"8","author":"NG Holtzman","year":"2024","unstructured":"Holtzman NG, Curtis LM, Salit RB, Shaffer BC, Pirsl F, Ostojic A et al (2024) High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood Adv 8(16):4294\u20134310. https:\/\/doi.org\/10.1182\/bloodadvances.2023010973","journal-title":"Blood Adv"},{"issue":"1","key":"6344_CR49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/bmt.2010.68","volume":"46","author":"N Schub","year":"2011","unstructured":"Schub N, G\u00fcnther A, Schrauder A, Claviez A, Ehlert C, Gramatzki M et al (2011) Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transpl 46(1):143\u2013147. https:\/\/doi.org\/10.1038\/bmt.2010.68","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"6344_CR50","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/bmt.2016.83","volume":"51","author":"SK Tey","year":"2016","unstructured":"Tey SK, Vuckovic S, Varelias A, Martins JP, Olver S, Samson L et al (2016) Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD. Bone Marrow Transpl 51(8):1153\u20131155. https:\/\/doi.org\/10.1038\/bmt.2016.83","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"6344_CR51","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/j.bbmt.2016.09.016","volume":"22","author":"P Khandelwal","year":"2016","unstructured":"Khandelwal P, Emoto C, Fukuda T, Vinks AA, Neumeier L, Dandoy CE et al (2016) A prospective study of alemtuzumab as a Second-Line agent for Steroid-Refractory acute Graft-versus-Host disease in pediatric and young adult allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 22(12):2220\u20132225. https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10266","key":"6344_CR52","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G et al (2020) Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396(10266):1885\u20131894. https:\/\/doi.org\/10.1016\/S0140-6736(20)32334-5","journal-title":"Lancet"},{"key":"6344_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.msard.2019.01.019","volume":"29","author":"S Vukusic","year":"2019","unstructured":"Vukusic S, Brassat D, de Seze J, Izquierdo G, Lysandropoulos A, Moll W et al (2019) Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD). Mult Scler Relat Disord 29:7\u201314. https:\/\/doi.org\/10.1016\/j.msard.2019.01.019","journal-title":"Mult Scler Relat Disord"},{"key":"6344_CR54","doi-asserted-by":"publisher","unstructured":"Caon C, Namey M, Meyer C, Mayer L, Oyuela P, Margolin DH et al (2015 Jul-Aug) Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(\u00ae) Efficacy in Multiple Sclerosis (CARE-MS) Program. Int J MS Care 17(4):191\u2013198. https:\/\/doi.org\/10.7224\/1537-2073.2014-030","DOI":"10.7224\/1537-2073.2014-030"},{"key":"6344_CR55","first-page":"1706","volume":"19","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Xie H, Cao M et al (2021) Adverse event signal mining and analysis of alemtuzumab based on FAERS database. Cent South Pharm 19:1706\u20131710","journal-title":"Cent South Pharm"},{"issue":"22","key":"6344_CR56","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1182\/blood-2011-07-365437","volume":"119","author":"S Lepretre","year":"2012","unstructured":"Lepretre S, Aurran T, Mah\u00e9 B, Cazin B, Tournilhac O, Maisonneuve H et al (2012) Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 119(22):5104\u20135110. https:\/\/doi.org\/10.1182\/blood-2011-07-365437","journal-title":"Blood"},{"issue":"8","key":"6344_CR57","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3109\/10428194.2012.659735","volume":"53","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T et al (2012) Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian lymphoma study group. Leuk Lymphoma 53(8):1515\u20131524. https:\/\/doi.org\/10.3109\/10428194.2012.659735","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"6344_CR58","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1080\/10428194.2020.1713322","volume":"61","author":"S Ichikawa","year":"2020","unstructured":"Ichikawa S, Fukuhara N, Saito K, Yokoyama H, Onodera K, Onishi Y et al (2020) Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab. Leuk Lymphoma 61(6):1504\u20131507. https:\/\/doi.org\/10.1080\/10428194.2020.1713322","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"6344_CR59","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1399-3062.2009.00414.x","volume":"11","author":"SH Park","year":"2009","unstructured":"Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim SH et al (2009) Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte Globulin. Transpl Infect Dis 11(5):413\u2013423. https:\/\/doi.org\/10.1111\/j.1399-3062.2009.00414.x","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"6344_CR60","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3346\/jkms.2010.25.4.630","volume":"25","author":"S Lee","year":"2010","unstructured":"Lee S, Kim SH, Choi SM, Lee DG, Kim SY, Lee JW et al (2010) Cytomegalovirus ventriculoencephalitis after unrelated double cord blood stem cell transplantation with an alemtuzumab-containing preparative regimen for Philadelphia-positive acute lymphoblastic leukemia. J Korean Med Sci 25(4):630\u2013633. https:\/\/doi.org\/10.3346\/jkms.2010.25.4.630","journal-title":"J Korean Med Sci"},{"issue":"4","key":"6344_CR61","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.leukres.2007.06.010","volume":"32","author":"WY Au","year":"2008","unstructured":"Au WY, Leung AY, Tse EW, Cheung WW, Shek TW, Kwong YL (2008) High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Leuk Res 32(4):547\u2013551. https:\/\/doi.org\/10.1016\/j.leukres.2007.06.010","journal-title":"Leuk Res"},{"key":"6344_CR62","doi-asserted-by":"publisher","first-page":"101503","DOI":"10.1016\/j.msard.2019.101503","volume":"38","author":"AY Lau","year":"2020","unstructured":"Lau AY, Lui GCY, Chan KP, Au C, Mok VCT, Ziemssen T (2020) Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis. Mult Scler Relat Disord 38:101503. https:\/\/doi.org\/10.1016\/j.msard.2019.101503","journal-title":"Mult Scler Relat Disord"},{"key":"6344_CR63","doi-asserted-by":"publisher","first-page":"8883183","DOI":"10.1155\/2020\/8883183","volume":"2020","author":"A Kaplan","year":"2020","unstructured":"Kaplan A, Young JH, Kandaswamy R, Berglund D, Knoll BM, Sieger G et al (2020) Long-Term infectious and noninfectious outcomes of monthly alemtuzumab as a calcineurin Inhibitor- and Steroid-Free regimen for pancreas transplant recipients. Can J Infect Dis Med Microbiol 2020:8883183. https:\/\/doi.org\/10.1155\/2020\/8883183","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"6344_CR64","doi-asserted-by":"publisher","first-page":"1343971","DOI":"10.3389\/fimmu.2024.1343971","volume":"15","author":"J Yang","year":"2024","unstructured":"Yang J, Sun Y, Zhou X, Zhang D, Xu Z, Cao J et al (2024) Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis. Front Immunol 15:1343971. https:\/\/doi.org\/10.3389\/fimmu.2024.1343971","journal-title":"Front Immunol"},{"issue":"2","key":"6344_CR65","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","volume":"86","author":"O Tuohy","year":"2015","unstructured":"Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N et al (2015) Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 86(2):208\u2013215. https:\/\/doi.org\/10.1136\/jnnp-2014-307721","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"6344_CR66","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1352458514549398","volume":"21","author":"HP Hartung","year":"2015","unstructured":"Hartung HP, Aktas O, Boyko AN (2015) Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler 21(1):22\u201334. https:\/\/doi.org\/10.1177\/1352458514549398","journal-title":"Mult Scler"},{"issue":"3","key":"6344_CR67","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/ajh.21086","volume":"83","author":"S Kako","year":"2008","unstructured":"Kako S, Kanda Y, Oshima K, Nishimoto N, Sato H, Watanabe T et al (2008) Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab. Am J Hematol 83(3):247\u2013249. https:\/\/doi.org\/10.1002\/ajh.21086","journal-title":"Am J Hematol"},{"issue":"11","key":"6344_CR68","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1007\/s00415-018-8822-y","volume":"265","author":"V Devonshire","year":"2018","unstructured":"Devonshire V, Phillips R, Wass H, Da Roza G, Senior P (2018) Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol 265(11):2494\u20132505. https:\/\/doi.org\/10.1007\/s00415-018-8822-y","journal-title":"J Neurol"},{"issue":"9","key":"6344_CR69","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/sj.bmt.1705145","volume":"36","author":"K Oshima","year":"2005","unstructured":"Oshima K, Sakata-Yanagimoto M, Asano-Mori Y, Izutsu K, Watanabe T, Shoda E et al (2005) Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transpl 36(9):821\u2013824. https:\/\/doi.org\/10.1038\/sj.bmt.1705145","journal-title":"Bone Marrow Transpl"},{"key":"6344_CR70","doi-asserted-by":"publisher","first-page":"102141","DOI":"10.1016\/j.msard.2020.102141","volume":"41","author":"MA Alnahdi","year":"2020","unstructured":"Alnahdi MA, Aljarba SI, Al Malik YM (2020) Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and stroke: A case report. Mult Scler Relat Disord 41:102141. https:\/\/doi.org\/10.1016\/j.msard.2020.102141","journal-title":"Mult Scler Relat Disord"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06344-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06344-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06344-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:51Z","timestamp":1749105471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06344-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6344"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06344-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}